Literature DB >> 23401297

XOMA 052, an anti-IL-1β monoclonal antibody, prevents IL-1β-mediated insulin resistance in 3T3-L1 adipocytes.

Masahisa Handa1, Sandra Vanegas, Betty A Maddux, Nerissa Mendoza, Shirley Zhu, Ira D Goldfine, Amer M Mirza.   

Abstract

OBJECTIVE: Interleukin-1β (IL-1β) has recently been implicated as a major cytokine that is involved in the pancreatic islet inflammation of type 2 diabetes mellitus. This inflammation impairs insulin secretion by inducing beta-cell apoptosis. Recent evidence has suggested that in obesity-induced inflammation, IL-1β plays a key role in causing insulin resistance in peripheral tissues. DESIGN AND METHODS: To further investigate the pathophysiological role of IL-1β in causing insulin resistance, the inhibitory effects of IL-1β on several insulin-dependent metabolic processes in vitro has been neutralized by XOMA 052. The role IL-1β plays in insulin resistance in adipose tissue was assessed using differentiated 3T3-L1 adipocytes and several parameters involved in insulin signaling and lipid metabolism were examined. RESULTS AND
CONCLUSION: IL-1β inhibited insulin-induced activation of Akt phosphorylation, glucose transport, and fatty acid uptake. IL-1β also blocked insulin-mediated downregulation of suppressor of cytokine signaling-3 expression. Co-preincubation of IL-1β with XOMA 052 neutralized nearly all of these inhibitory effects in 3T3-L1 adipocytes. These studies provide evidence, therefore, that IL-1β is a key proinflammatory cytokine that is involved in inducing insulin resistance. These studies also suggest that the monoclonal antibody XOMA 052 may be a possible therapeutic to effectively neutralize cytokine-mediated insulin resistance in adipose tissue.
Copyright © 2012 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23401297     DOI: 10.1002/oby.20004

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  4 in total

Review 1.  Targeting adipose tissue in the treatment of obesity-associated diabetes.

Authors:  Christine M Kusminski; Perry E Bickel; Philipp E Scherer
Journal:  Nat Rev Drug Discov       Date:  2016-06-03       Impact factor: 84.694

Review 2.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

3.  Interleukin-1β-Targeted Vaccine Improves Glucose Control and β-Cell Function in a Diabetic KK-Ay Mouse Model.

Authors:  Jun Zha; Xiao-Wei Chi; Xiao-Lin Yu; Xiang-Meng Liu; Dong-Qun Liu; Jie Zhu; Hui Ji; Rui-Tian Liu
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

Review 4.  Vaccine for Diabetes-Where Do We Stand?

Authors:  Dinesh Kumar Chellappan; Richie R Bhandare; Afzal B Shaik; Krishna Prasad; Nurfatihah Azlyna Ahmad Suhaimi; Wei Sheng Yap; Arpita Das; Pradipta Banerjee; Nandini Ghosh; Tanner Guith; Amitava Das; Sarannya Balakrishnan; Mayuren Candasamy; Jayashree Mayuren; Kishneth Palaniveloo; Gaurav Gupta; Sachin Kumar Singh; Kamal Dua
Journal:  Int J Mol Sci       Date:  2022-08-22       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.